CN103877581A - Bazedoxifene acetate sustained release preparation with excellent performance - Google Patents
Bazedoxifene acetate sustained release preparation with excellent performance Download PDFInfo
- Publication number
- CN103877581A CN103877581A CN201410109188.3A CN201410109188A CN103877581A CN 103877581 A CN103877581 A CN 103877581A CN 201410109188 A CN201410109188 A CN 201410109188A CN 103877581 A CN103877581 A CN 103877581A
- Authority
- CN
- China
- Prior art keywords
- preparation
- weight
- percentage
- acetic acid
- hydrophobicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a bazedoxifene acetate sustained release preparation with excellent performance and a preparation process thereof. The preparation is a sustained release dropping pill, which comprises the following components in percentage by weight: 1-25 percent of bazedoxifene acetate, 40-70 percent of hydrophobic dropping pill matrix, and 5-40 percent of hydrophilic matrix. The sustained release dropping pill has a higher chemical stability, physical stability (low-crystal form conversion rate) and in-vivo drug-release behavior (higher bioavailability and smooth and durable plasma concentration).
Description
[technical field]
The present invention relates to a kind of particularly stable WAY 140424 preparation of excellent performance.More particularly, the present invention relates to a kind of particularly stable acetic acid WAY 140424 slow releasing preparation and preparation technology thereof of excellent performance.
[technical background]
WAY 140424 (bazedoxifene) SERM WAY 140424 of new generation, contestable suppresses the combination of 1,713 one estradiol and estrogen receptor ERoc and ER13, skeleton is had to estrogen agonist activity, can improve the bone density of vertebra and hip, therefore can significantly reduce the vertebral fracture risk of osteoporosis menopausal women.Its principal indications is sclerotin for prevention with after treating menopause.
The chemical name of acetic acid WAY 140424 is (1-[4-(2-azacyclo-heptan-1-base-ethyoxyl)-benzyl]-2-(4-hydroxyl-phenyl)-3-Methyl-1H-indole-5-ol acetic acid), has chemical constitution as follows:
In US2005/0227965, disclose the polymorphic A of acetic acid WAY 140424, and in US2005/0250762, disclosed the polymorph b of acetic acid WAY 140424.In aqueous and organic solvent system, crystal form A is higher than the dissolubility of crystal form B.In this preparation at the dissolubility of concern particular composition or administration, be particularly advantageous.For example, higher dissolubility can affect bioavailability, and bioavailability affects bio-absorbable and the distribution of medicine, and can be conducive to the preparation in liquid-carrier.But crystal form A is the dynamic polymorphic of (or metastable state), and the crystal form B more stable polymorphic that is thermodynamics.Crystal form A can be transformed at leisure crystal form B in preparation preparation and storage.The crystallization polymorphism of this medicine affects the interior pharmacological characteristics of convenience, stability, dissolubility, storage stability, preparation convenience and body prepared by this medicine conventionally.
WAY 140424 grinds by Hui Shi is former, after transfer Pfizer, April 27 in 2009, the approval by European Bureau of Drugs Supervision was gone on the market in Italy and Spain, commodity are called Conbriza, go on the market in July, 2010 in Japan, commodity are called Viviant.Listing dosage form is conventional formulation, and blood drug level has certain undulatory property, will produce certain clinical adverse, therefore,, if be made into the blood drug level that slow releasing preparation is conducive to control medicine, make its long lasting and stable effective, reach efficient and long-acting object simultaneously, and can improve compliance.There is no at present the development report of its slow releasing preparation.
[goal of the invention]
Goal of the invention is just to provide a kind of particularly slow releasing preparation of stable WAY 140424 of excellent performance.Particularly, the object of this invention is to provide a kind of particularly stable acetic acid WAY 140424 sustained-release dropping pill and preparation technology thereof of excellent performance.
[summary of the invention]
The present invention relates to a kind of acetic acid WAY 140424 sustained-release dropping pill of excellent performance, this sustained-release dropping pill comprises that percentage by weight is 1-25% (preferably 2-20%, more preferably 2-15%, most preferably 2-10%) active component acetic acid WAY 140424, percentage by weight is 40-70% (preferably 45-70%, more preferably 50-70%, most preferably 60-70%) hydrophobicity Basic compose, and percentage by weight is respectively 5-40% (preferably 10-40%, more preferably 15-35%, most preferably 20-30%) hydrophilic matrix, above-mentioned percentage by weight is take whole drop pill gross weight as basis.
The hydrophobicity Basic compose the present invention relates to is selected from but is not limited to stearic acid, octadecanol, glycerol monostearate acid, fat insect wax etc.; The hydrophilic matrix the present invention relates to is selected from vitamin E TPGS.
Vitamin E TPGS, regulates outside the drug release rate of sustained-release dropping pill except making hydrophilic matrix in the present invention, also has following prior effect:
1), acetic acid WAY 140424 (having phenolic hydroxyl group) is oxidizable, vitamin E TPGS makes antioxidant, can improve the chemical stability of acetic acid WAY 140424 sustained-release dropping pill in the processes such as preparation, storage;
2), the vitamin E TPGS water soluble surfactant active that is low melting point, can make acetic acid WAY 140424 be easy to disperse at hydrophobicity Basic compose, and can make it be easy to stripping at aqueous medium, thereby improve bioavailability in the preparation convenience of its preparation and body;
3), vitamin E TPGS is as surfactant, there is good affinity with acetic acid WAY 140424 and hydrophobicity Basic compose, vitamin E TPGS and the coupling of hydrophobicity Basic compose are conducive to slow down acetic acid WAY 140424 crystal form A and change to crystal form B in preparation preparation and storage, improve the physical stability of acetic acid WAY 140424 preparation, thereby can improve bioavailability in its body.
The acetic acid WAY 140424 sustained-release dropping pill the present invention relates to can also comprise lipophile antioxidant, such as, in vitamin E, Propylgallate and BHA/BHT etc. at least one, the percentage by weight of above-mentioned lipophile antioxidant in drop pill, 0.1-15% (preferably 0.5-10%, more preferably 1-8%, most preferably 1-5%), above-mentioned percentage by weight is take whole drop pill gross weight as basis.
The acetic acid WAY 140424 sustained-release dropping pill the present invention relates to can also comprise other hydrophilic Basic composes, for example Polyethylene Glycol, polyethylene glycol-propylene glycol copolymers, polyoxyethylene groups (40) stearate, the percentage by weight of above-mentioned hydrophilic Basic compose in drop pill is 1-40% (preferably 5-30%, more preferably 10-25%, most preferably 10-20%), above-mentioned percentage by weight is take whole drop pill gross weight as basis.
The sustained-release dropping pill the present invention relates to can also comprise other wetting agents, for example sucrose palmitate, metal alkyl sulfate, sodium lauryl sulfate, polyoxyethylene sorbitan carboxylic ester, polyoxyethylene alkyl ether, castor oil derivatives, many storehouse acid sodium, quaternary ammonium compound, the sugar ester of fatty acid, polyethoxylated fatty acid ester, at least one in glyceride and the polyglycolyzed glyceride of fatty acid, the percentage by weight of above-mentioned wetting agent in drop pill, 0.1-15% (preferably 0.5-10%, more preferably 1-8%, most preferably 1-5%), above-mentioned percentage by weight is take whole drop pill gross weight as basis.
The preparation technology of the sustained-release dropping pill the present invention relates to comprises after hydrophilic matrix heat fused, after adding acetic acid WAY 140424 to mix, add again hydrophobicity Basic compose to mix rear one-tenth suspension, suspension is inserted to the dripping in tank with water dropper of insulation, splash in condensed fluid, be condensed into spherical, after blotting finished product.Heat fused temperature is 80-i00 ℃; Suspension is incubated the temperature splashing in condensed fluid and is controlled at 80-110 ℃.The preparation technology of the sustained-release dropping pill the present invention relates to is simple, with low cost.
For achieving the above object, the preferred following technical scheme of the present invention: the acetic acid WAY 140424 fine powder of 2-20% percentage by weight is added in the substrate of melting of 80-98% percentage by weight, fully mixes, dropping preparation method is condensed into ball in coolant, except coolant, dry, to obtain final product.
Coolant in the present invention includes but not limited to dimethicone, liquid paraffin, plant wet goods, with dimethicone the best.
The external diameter of above-mentioned sustained-release dropping pill is preferably 0.5-5mm, is more preferably 1-4mm.
Above-mentioned sustained-release dropping pill is filled in and in capsule, makes capsule.
Acetic acid WAY 140424 is made to sustained-release dropping pill, be conducive to the long lasting and stable of blood drug level, avoid or reduce the generation of side effect, improve compliance.
Accompanying drawing explanation
Fig. 1: the release test result of active component in embodiment 1-4 sample
Fig. 2: experimental example 3 and reference examples 1 blood drug level test result
[embodiment]
Embodiment 1
Prescription: every 1000 consumptions:
Acetic acid WAY 140424 2.26g
Vitamin E TPGS 5.0g
Stearic acid 42.74g
Specification: drug content 2.26mg/ grain, the heavy 50mg/ grain of ball.
Technique: more than acetic acid WAY 140424 raw material pulverizing, porphyrize are reached to 150 orders; Take vitamin E TPGS, stearic acid by prescription; By after hydrophilic matrix heat fused, add again hydrophobicity Basic compose to mix rear one-tenth suspension after adding acetic acid WAY 140424 to mix; By above-mentioned eutectic liquids 80-85 ℃ of insulation; Above-mentioned solution is transferred to dripping in dripping device, and solution temperature is controlled at 80-85 ℃, splashes in the dimethicone of room temperature, pulls to the greatest extent silicone oil of drop out, the silicone oil of drop pill surface attachment is cleaned with absorbent gauze.
Prescription: every 1000 consumptions:
Acetic acid WAY 140424 4.52g
Vitamin E TPGS 10.0g
Glycerol monostearate acid 35.48g
Specification: drug content 4.52mg/ grain, the heavy 50mg/ grain of ball.
Technique: more than acetic acid WAY 140424 raw material pulverizing, porphyrize are reached to 150 orders; Take vitamin E TPGS, glycerol monostearate acid by prescription; By after hydrophilic matrix heat fused, add again hydrophobicity Basic compose to mix rear one-tenth suspension after adding acetic acid WAY 140424 to mix; By above-mentioned eutectic liquids 80-90 ℃ of insulation; Above-mentioned solution is transferred to dripping in dripping device, and solution temperature is controlled at 80-90 ℃, splashes in the dimethicone of room temperature, pulls to the greatest extent silicone oil of drop out, the silicone oil of drop pill surface attachment is cleaned with absorbent gauze.
Prescription: every 1000 consumptions:
Acetic acid WAY 140424 2.26g
Vitamin E TPGS 15.0g
Octadecanol 32.74g
Specification: drug content 2.26mg/ grain, the heavy 50mg/ grain of ball.
Technique: more than acetic acid WAY 140424 raw material pulverizing, porphyrize are reached to 150 orders; Take vitamin E TPGS, octadecanol by prescription; By after hydrophilic matrix heat fused, add again hydrophobicity Basic compose to mix rear one-tenth suspension after adding acetic acid WAY 140424 to mix; By above-mentioned eutectic liquids 80-90 ℃ of insulation; Above-mentioned solution is transferred to dripping in dripping device, and solution temperature is controlled at 80-90 ℃, splashes in the dimethicone of room temperature, pulls to the greatest extent silicone oil of drop out, the silicone oil of drop pill surface attachment is cleaned with absorbent gauze.
Embodiment 4
Prescription: every 1000 consumptions:
Acetic acid WAY 140424 4.52g
Vitamin E TPGS 20.0g
Fat insect wax 25.48g
Specification: drug content 4.52mg/ grain, the heavy 50mg/ grain of ball.
Technique: more than acetic acid WAY 140424 raw material pulverizing, porphyrize are reached to 150 orders; Take vitamin E TPGS, fat insect wax by prescription; By after hydrophilic matrix heat fused, add again hydrophobicity Basic compose to mix rear one-tenth suspension after adding acetic acid WAY 140424 to mix; By above-mentioned eutectic liquids 80-85 ℃ of insulation; Above-mentioned solution is transferred to dripping in dripping device, and solution temperature is controlled at 80-85 ℃, splashes in the dimethicone of room temperature, pulls to the greatest extent silicone oil of drop out, the silicone oil of drop pill surface attachment is cleaned with absorbent gauze.
Test example 1 prepare and storage in principal agent stability test
Experimental example sample: the sample (altogether containing bazedoxifene acetate (BZA) 22.6mg, closing WAY 140424 20mg in sample) of preparing in embodiment 1-4
Reference examples sample 1: bazedoxifene acetate (BZA) sheet 1 (specification: every contains bazedoxifene acetate (BZA) 22.6mg, closes WAY 140424 20mg) of commodity Viviant by name (comprises BZA crystal form A, lactose monohydrate, ascorbic acid, microcrystalline Cellulose, pregelatinized Starch, sodium starch glycollate, colloidal silica, magnesium stearate and sodium lauryl sulphate.This tablet comprises and contains
white and
the coatings of Clear.)
Reference substance 2: bazedoxifene acetate (BZA) sheet 2 (wherein ascorbic acid is substituted by vitamin E TPGS, and other are all constant) of preparing with reference to the bazedoxifene acetate sheet of commodity Viviant by name.
Illustrate: the active component in above-mentioned homemade experimental example 1-4 and reference examples sample 2 all derives from same batch of sample, the ratio that bazedoxifene acetate crystal form B accounts in total bazedoxifene acetate is 0.56%.
Above-mentioned experimental example and reference examples sample are inserted lower 30 days of the environment of 40 ℃ of temperature and relative humidity 90% and within 60 days, are detected afterwards the content of bazedoxifene acetate (relatively labelled amount) and bazedoxifene acetate crystal form B accounts for ratio in total bazedoxifene acetate (assay method is referring to CN101657421A).The results are shown in Table 1:
The content (labelled amount relatively) of table 1 bazedoxifene acetate and bazedoxifene acetate crystal form B account for the measurement result of ratio in total bazedoxifene acetate
Result demonstration, embodiment sample has higher chemical stability and physical stability (lower crystal formation conversion ratio) compared with reference examples sample active component.Result also shows simultaneously, and in embodiment sample preparation process, active component crystal formation conversion ratio is starkly lower than reference examples 2.
The release of active component and blood drug level test in test example 2 embodiment samples
Experimental example sample: the sample (altogether containing bazedoxifene acetate (BZA) 22.6mg, closing WAY 140424 20mg in sample) of preparing in embodiment 1-4
Reference examples sample 1: bazedoxifene acetate (BZA) sheet 1 (specification: every contains bazedoxifene acetate (BZA) 22.6mg, closes WAY 140424 20mg) of commodity Viviant by name
The release of measuring active component in (using HPLC method) embodiment 1-4 sample, the results are shown in accompanying drawing 1.
Take BEAGLE dog as subjects, single dose intersection oral administration: 10, the sample that once takes respectively preparation in embodiment 3 (contains bazedoxifene acetate (BZA) 22.6mg altogether in sample, close WAY 140424 20mg) and 1 one, reference examples sample (in sample altogether containing bazedoxifene acetate (BZA) 22.6mg, close WAY 140424 20mg), within one day, be administered once, measure blood drug level, the results are shown in Figure 2.
Result demonstration, experimental example has blood drug level very stably compared with reference examples.
Claims (18)
1. the acetic acid WAY 140424 preparation of an excellent performance, it is characterized in that said preparation is sustained-release dropping pill, this sustained-release dropping pill comprises that percentage by weight is the acetic acid WAY 140424 of 1-25%, percentage by weight is the hydrophobicity Basic compose of 40-70%, and percentage by weight is respectively the hydrophilic matrix of 5-40%, above-mentioned hydrophobicity Basic compose is selected from but at least one in stearic acid, octadecanol, glycerol monostearate acid, fat insect wax, above-mentioned hydrophilic matrix is selected from vitamin E TPGS, and above-mentioned percentage by weight is take whole drop pill gross weight as basis.
2. according to the preparation of claim 1, it is characterized in that the percentage by weight of described acetic acid WAY 140424 is 2-20%, the percentage by weight of described hydrophobicity Basic compose is 45-70%, and the percentage by weight of described hydrophilic matrix is respectively 10-40%.
3. according to the preparation of claim 1, it is characterized in that the percentage by weight of described acetic acid WAY 140424 is 2-15%, the percentage by weight of described hydrophobicity Basic compose is 50-70%, and the percentage by weight of described hydrophilic matrix is respectively 15-35%.
4. according to the preparation of claim 1, it is characterized in that the percentage by weight of described acetic acid WAY 140424 is 2-10%, the percentage by weight of described hydrophobicity Basic compose is 60-70%, and the percentage by weight of described hydrophilic matrix is respectively 20-30%.
5. according to the preparation of claim 1, it is characterized in that described hydrophobicity Basic compose is selected from but at least one in stearic acid, octadecanol.
6. according to the preparation of claim 1, it is characterized in that said preparation comprises lipophile antioxidant.
7. according to the preparation of claim 6, it is characterized in that described lipophile antioxidant is selected from least one in vitamin E, Propylgallate and BHA/BHT.
8. according to the preparation of claim 1, it is characterized in that at least one in glyceride and the polyglycolyzed glyceride of sugar ester that said preparation comprises sucrose palmitate, metal alkyl sulfate, sodium lauryl sulfate, polyoxyethylene sorbitan carboxylic ester, polyoxyethylene alkyl ether, castor oil derivatives, many storehouses acid sodium, quaternary ammonium compound, fatty acid, polyethoxylated fatty acid ester, fatty acid.
9. according to the preparation of claim 1, it is characterized in that said preparation comprises at least one in Polyethylene Glycol, polyethylene glycol-propylene glycol copolymers, polyoxyethylene groups (40) stearate.
10. according to the preparation of claim 1, it is characterized in that the external diameter of described sustained-release dropping pill is 0.5-5mm.
11. according to the preparation of claim 1, it is characterized in that the external diameter of described sustained-release dropping pill is 1-4mm.
12. 1 kinds of capsules, is characterized in that this capsule comprises according to any one preparation in claim 1 to 11.
13. comprise after described hydrophilic matrix heat fused according to the preparation method of any one preparation in claim 1 to 11, after adding acetic acid WAY 140424 to mix, add again described hydrophobicity Basic compose to mix rear one-tenth suspension, again suspension is inserted to the dripping in tank with water dropper of insulation, splash in condensed fluid, be condensed into spherical, after blotting drop pill finished product.
14. according to the preparation method of claim 13, it is characterized in that described condensed fluid is selected from dimethicone, liquid paraffin or vegetable oil.
15. according to the preparation method of claim 13, it is characterized in that described condensed fluid is selected from dimethicone.
16. according to the preparation method of claim 13, and the temperature that it is characterized in that described heat fused is 80-100 ℃.
17. according to the preparation method of claim 13, it is characterized in that comprising that the temperature that described suspension splashes in described condensed fluid is controlled at 80-110 ℃.
18. according to the preparation method of claim 13, it is characterized in that described preparation is filled in capsule and makes capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410109188.3A CN103877581B (en) | 2014-03-24 | 2014-03-24 | A kind of acetic acid Bazedoxifene slow releasing preparation of excellent performance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410109188.3A CN103877581B (en) | 2014-03-24 | 2014-03-24 | A kind of acetic acid Bazedoxifene slow releasing preparation of excellent performance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103877581A true CN103877581A (en) | 2014-06-25 |
| CN103877581B CN103877581B (en) | 2016-03-02 |
Family
ID=50946915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410109188.3A Active CN103877581B (en) | 2014-03-24 | 2014-03-24 | A kind of acetic acid Bazedoxifene slow releasing preparation of excellent performance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103877581B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101304731A (en) * | 2005-08-24 | 2008-11-12 | 惠氏公司 | Bazedoxifene acetate formulations and preparation method |
| CN101977897A (en) * | 2008-02-11 | 2011-02-16 | 惠氏有限责任公司 | Methods of preparing polymorphic form a of bazedoxifene acetate |
| WO2011056532A2 (en) * | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
| CN103494787A (en) * | 2013-07-22 | 2014-01-08 | 南通广泰生化制品有限公司 | Tamoxifen citrate dropping pill |
-
2014
- 2014-03-24 CN CN201410109188.3A patent/CN103877581B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101304731A (en) * | 2005-08-24 | 2008-11-12 | 惠氏公司 | Bazedoxifene acetate formulations and preparation method |
| CN101977897A (en) * | 2008-02-11 | 2011-02-16 | 惠氏有限责任公司 | Methods of preparing polymorphic form a of bazedoxifene acetate |
| WO2011056532A2 (en) * | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
| CN103494787A (en) * | 2013-07-22 | 2014-01-08 | 南通广泰生化制品有限公司 | Tamoxifen citrate dropping pill |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103877581B (en) | 2016-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103998041B (en) | Pharmaceutical composition | |
| CN102036654B (en) | Stabilized atypical antipsychotic formulation | |
| US4717569A (en) | Unit dosage form of sparingly soluble medicaments | |
| JP4653810B2 (en) | Butylphthalide self-emulsifying drug delivery system, method for its preparation and use | |
| CN105873566B (en) | The purposes of compressed tablets containing Δ 9- tetrahydrocannabinol, its manufacturing method and such tablet in oral medication | |
| US20020160041A1 (en) | Controlled release pharmaceutical composition | |
| CN108354930A (en) | Include the pharmaceutical preparation of 1- (β-D- glucopyranosyls) -2- thienyl-methyl benzene derivatives | |
| CN105246464A (en) | Stabilized modified release vitamin d formulation and method of administring same | |
| JP2008510737A5 (en) | ||
| CN107995862A (en) | Include the liquid medicine composition of SGLT-2 inhibitor | |
| CZ152094A3 (en) | Pharmaceutical preparation for reducing concentration of glucose in blood | |
| NO179163B (en) | Process for the preparation of a sustained release drug preparation | |
| JP2008536879A (en) | Drug or nutrition combination preparation and preparation, method for improving absorption by internal use, and application method thereof | |
| AU2018332191B2 (en) | Pharmaceutical composition | |
| WO2008022557A1 (en) | Liquid composition of sirolimus | |
| CN103877581B (en) | A kind of acetic acid Bazedoxifene slow releasing preparation of excellent performance | |
| CN105616557A (en) | Self-emulsifying soft capsule with peony seed oil and application of self-emulsifying soft capsule to preparing blood fat reducing healthcare products or medicines | |
| CN108066312A (en) | A kind of Pa Boxini pharmaceutical compositions and preparation method thereof | |
| CN103845336B (en) | A kind of acetic acid Bazedoxifene compositions of excellent performance | |
| CN109700777A (en) | A kind of pH dependent form drug hydrophobic framework sustained release tablets and preparation method thereof | |
| EA015440B1 (en) | Solid dosage form containing clopidogrel hydrogenesulphate of polymorph form 1 | |
| KR20200135400A (en) | Topical composition | |
| CN104644595A (en) | Solid pharmaceutical composition with clopidogrel | |
| CN102697765B (en) | Ranitidine hydrochloride/bismuth potassium citrate pharmaceutical composition solid lipid nanoparticles preparation | |
| CN105012961A (en) | Stable pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 214000, 35, Jing Xin Road, tin Beizhen Industrial Park, Xishan District, Jiangsu, Wuxi Applicant after: JIANGSU ZEYUN PHARMACEUTICAL CO., LTD. Address before: 214111 Jiangsu Province, Wuxi City District Town Square Xinming Road No. 29 Applicant before: Jiangsu Sempoll Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: JIANGSU SHENGBAOLUO MEDICINE INDUSTRY CO., LTD. TO: JIANGSU ZHIYUAN PHARMACEUTICAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: No. 35, Jingxin Road, industrial park, Xibei Town, Xishan District, Wuxi City, Jiangsu Province, 214000 Patentee after: Jiangsu Zhiyuan Pharmaceutical Co.,Ltd. Address before: No. 35, Jingxin Road, industrial park, Xibei Town, Xishan District, Wuxi City, Jiangsu Province, 214000 Patentee before: JIANGSU ZHIYUAN PHARMACEUTICAL Co.,Ltd. |